Think of Verquvo as a "Niche" Med for Heart Failure

Reps will tout Verquvo (vericiguat) as a new once-daily add-on for worsening heart failure with reduced ejection fraction (HFrEF).

Verquvo is the first "soluble guanylate cyclase stimulator" for HFrEF. It relaxes blood vessels through the nitric oxide pathway.

Most evidence is in patients already on triple therapy...an ACEI, ARB, or Entresto (sacubitril/valsartan), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote